UPSC Editorial Digest · June 6, 2026
Contents
Editorial Analysis
Premium analytical notes for GS answers, essay, interview and revision
Contents
01
Rates on Hold, Focus on Bringing Foreign Capital
GS 3 — Economy & Monetary Policy
GS 2 — Governance
Essay
02
India Needs Innovative Strategies to Eliminate TB
GS 2 — Health & Governance
GS 3 — Science & Technology
Essay
Editorial 01 of 02
Article 01
Rates on Hold, Focus on Bringing Foreign Capital
Relevance: Monetary Policy Committee (MPC) mandate, RBI-Government coordination, capital account management, exchange rate defence, and foreign capital attraction — directly linked to the June 5, 2026 policy decision; high-value for GS 3 (Economy), GS 2 (Governance) and Interview rounds covering current economic affairs.
GS 3 — Economy & Monetary Policy
GS 2 — Governance & Institutions
Essay — Growth vs Stability
1 — Issue in Brief
- The June 5, 2026 MPC meeting took place against a difficult backdrop: inflationary pressures building, capital fleeing, the rupee under pressure, and growth momentum uncertain. Despite calls for a rate hike, the MPC unanimously held the repo rate at 5.25% with a neutral stance — a decision the editorial endorses as appropriate given the prevailing uncertainty.
- The West Asia conflict is the central macro disruptor: elevated crude oil prices are simultaneously pushing up inflation, widening India’s Current Account Deficit (CAD), squeezing corporate margins, and triggering a global risk-off sentiment that has driven foreign capital out of Indian equity markets at an unprecedented pace in 2026.
- The editorial’s core argument: the MPC correctly stayed within its inflation-targeting mandate (rates), while the RBI and the Government separately deployed coordinated capital account tools — tax exemptions, FAR expansion, forex swap facilities — to address the rupee’s weakness through the appropriate institutional channel.
- The scale of the capital flight makes these measures urgent: foreign investors pulled out $28.6 billion from Indian equity markets in CY2026 so far — already exceeding the full-year 2025 outflow — while net FDI stood at just $7.65 billion in 2025-26, well below the levels needed to comfortably finance a widening CAD.
2 — Static Background
- The Monetary Policy Committee (MPC) was established under the RBI Act (amended 2016) as a six-member body — three RBI officials including the Governor (chairperson), and three external members appointed by the Government. Its sole statutory mandate is CPI inflation targeting within the 4% ±2% band (i.e., 2–6%). Exchange rate and capital account management fall under the RBI’s broader mandate, not the MPC’s.
- India’s rate cycle context: After holding at 6.5% for 11 consecutive meetings, the RBI cut rates by a cumulative 125 bps starting February 2025. The current repo rate of 5.25% reflects significant prior easing. The June 2026 decision marks the second bi-monthly meeting of FY2027, with the MPC having shifted its stance from accommodative to neutral in mid-2025.
- The Fully Accessible Route (FAR) is an RBI framework under which specified Government Securities (G-secs) have no investment limits for Foreign Portfolio Investors (FPIs) — unlike the General Route which has sub-limits. India’s inclusion in the JPMorgan GBI-EM index (June 2024) and the Bloomberg EM Local Currency Bond Index (January 2026) was premised on FAR securities being freely accessible to passive index-tracking funds globally.
- FCNR(B) deposits (Foreign Currency Non-Resident Bank) are held by NRIs in foreign currency with Indian banks. Both principal and interest are freely repatriable. Banks face hedging costs when deploying these foreign currency deposits domestically — the RBI’s concessional hedging facility directly subsidises this cost, incentivising banks to aggressively mobilise fresh FCNR(B) deposits from the large Indian diaspora.
- The Income-tax Amendment Ordinance, 2026 (deemed to have come into force April 1, 2026) inserted two new exemptions: Entry 13D exempts FII capital gains on G-sec sales and interest income; Entry 13E extends the same to the Bank for International Settlements. This removes the tax friction that limited active fund participation beyond passive index-tracking inflows triggered by the JPMorgan and Bloomberg inclusions.
- El Niño refers to periodic warming of Pacific Ocean surface temperatures that disrupts global weather patterns, typically reducing India’s southwest monsoon rainfall — directly threatening Kharif crop output, pushing food inflation higher, and reducing rural demand. The 2026 monsoon forecast is subnormal, compounding the inflationary pressure from the West Asia energy shock simultaneously.
3 — Key Dimensions
- The inflation trajectory: Headline retail CPI stood at 3.5% in April 2026 — deceptively low because fuel price hikes came in May. The MPC has already raised the FY27 CPI forecast to 5.1% from 4.6%, with significant upside risks from generalisation of food and fuel price pressures into core CPI (non-food, non-fuel). Core CPI is currently ~4.7% — rising but within the upper tolerance band of 6%.
- The growth-inflation dilemma: The MPC simultaneously cut GDP growth projection to 6.6% (from 6.9%) and raised inflation to 5.1% — a stagflationary signal that makes policy unusually difficult. Raising rates to fight inflation risks crushing already-slowing growth; holding rates risks inflation expectations de-anchoring if food and energy shocks prove persistent.
- The real policy rate argument: At 5.25% repo and 5.1% projected CPI, the real policy rate is barely 0.15% — near zero. Some market participants argued this compressed real rate warranted an immediate hike. The MPC and editorial disagree: inflation is still within the 6% band, growth risks are real, and a supply-side inflation driven by crude and monsoon cannot be meaningfully addressed by rate hikes.
- Capital flight — the structural pressure: FIIs pulled out $28.6 billion from Indian equities in CY2026 (Jan–Jun) — already exceeding the entire $26 billion five-month outflow record. Net FPI was -$16.7 billion in FY2025-26 (provisional). Drivers: sticky US interest rates keeping US Treasuries attractive, India’s MSCI EM weight reduction shifting passive funds toward Taiwan and South Korea, elevated crude risk premium, and India-specific valuation concerns.
- CAD widening: Elevated crude oil prices directly enlarge India’s import bill. India imports ~85% of its crude oil requirement. A $10/barrel increase in crude prices widens India’s CAD by approximately 0.4% of GDP. At $95+/barrel sustained through FY27, the CAD is expected to more than double to ~2% of GDP from sub-1% in recent years — materially increasing the financing requirement from volatile portfolio and FDI flows.
- The capital account policy package: Three coordinated instruments: (1) Tax exemption on G-sec gains/income for FIIs — removes friction blocking active fund participation post-index inclusion; (2) FAR expansion to new 15/30/40-year G-secs — deepens the investable universe for international long-duration bond funds; (3) Concessional forex swap and FCNR(B) hedging facility — incentivises stable, longer-tenor diaspora capital inflows that are less volatile than portfolio flows.
4 — Critical Analysis
- Favour — MPC institutional integrity preserved: Holding rates despite rupee pressure demonstrates that the MPC correctly treats exchange rate management as outside its inflation-targeting mandate — a separation essential for monetary policy credibility. Hiking rates to defend the currency would have blurred institutional roles and potentially triggered contractionary dynamics incompatible with the growth outlook.
- Favour — Tax exemption removes a structural barrier: The G-sec capital gains and withholding tax exemption is not just a short-term inducement — it removes a structural compliance friction that prevented many foreign institutional mandates (especially US-domiciled funds) from participating in India’s G-sec market even after JPMorgan and Bloomberg index inclusions. The ordinance route signals urgency and commitment.
- Favour — FAR expansion creates Bloomberg alignment: Bloomberg EM Local Currency Bond Index inclusion (January 2026) was the immediate trigger for FAR expansion. Adding long-duration securities (15/30/40-year) to the FAR signals India’s intent to develop a deep, internationally integrated sovereign bond market — a prerequisite for sustained non-volatile foreign debt capital.
- Concern — Supply-side inflation beyond rate-tool reach: If the West Asia conflict persists and El Niño reduces monsoon rainfall materially, both energy and food inflation will continue rising regardless of the repo rate. The MPC’s tools address demand-side inflation; the current inflation is predominantly supply-driven — meaning rate hikes would slow growth without meaningfully reducing prices, the worst of both outcomes.
- Concern — FCNR(B) subsidy creates contingent liability: The RBI bearing hedging costs for FCNR(B) deposits is a balance-sheet transfer from the central bank to attract diaspora capital. The 2013 Rajan-era FCNR(B) scheme raised ~$34 billion but created significant rollover risk when deposits matured in 2016 — requiring careful RBI forward management to avoid a repeat maturity wall of foreign currency obligations.
- Concern — Portfolio flows are inherently volatile: All the announced measures primarily attract FPI flows (bonds and equities) which are inherently reversible — the same investors who drove the $28.6 billion outflow in 2026 can return and exit again based on global risk-on/risk-off cycles. What India needs structurally is higher-quality, longer-duration FDI flows, which require broader reforms beyond tax and forex swap incentives.
5 — Way Forward
- October and December 2026 MPC meetings are live for rate hike(s) — the editorial signals that the next move on rates is a hike, conditional on monsoon impact clarity and evidence that food/fuel price increases have generalised into core inflation. Premature action risks growth; delayed action risks inflation expectations de-anchoring above the 6% upper bound.
- Deepen FDI structural reforms — the $7.65 billion net FDI figure for 2025-26 reflects repatriation-heavy outflows overwhelming improving gross inflows ($94.5 billion gross). India must accelerate ease of doing business, reduce regulatory unpredictability in key FDI-receiving sectors (electronics, defence, pharma), and resolve pending bilateral investment treaty renegotiations to improve net FDI quality and stability.
- Actively pursue Bloomberg full inclusion — the January 2026 Bloomberg EM index inclusion was an important step but India must ensure settlement infrastructure, operational ease, and the new tax exemption framework together make Indian G-secs fully operational for active fund participation — which would bring far larger and more stable inflows than passive index rebalancing alone.
- Manage the FCNR(B) maturity wall proactively — fresh 3–5 year FCNR(B) deposits raised now will mature in 2029–2031. RBI must build forward swap positions now to ensure these maturities do not create concentrated pressure on the rupee at the point of redemption, replicating the well-managed 2016 unwinding of the 2013 Rajan scheme rather than letting it become a balance-of-payments event.
6 — Data & Key Facts
5.25%Repo rate held unanimously by MPC on June 5, 2026; neutral stance maintained
5.1%RBI’s revised CPI inflation forecast for FY27 (raised 50 bps from 4.6% in April MPC)
6.6%RBI’s revised GDP growth forecast for FY27 (cut 30 bps from 6.9% in April MPC)
$28.6 BnFII equity outflows from India in CY2026 so far — exceeding full-year 2025 total outflow
$7.65 BnNet FDI inflows in 2025-26 (vs. gross FDI of $94.5 bn; repatriation remains high)
~2% GDPProjected CAD for FY27 (more than double the sub-1% of recent years) due to crude surge
- FII capital flight context: FIIs withdrew >₹2.54 lakh crore (~$28.6 billion) from Indian secondary equity markets in the first ~96 trading sessions of 2026 — at an average pace of over ₹400 crore per trading hour, compared to ₹161 crore per hour across all 241 sessions in 2025. The acceleration reflects confluence of crude shock, US rate stickiness, MSCI EM weight reduction, and India-specific valuation concerns.
- JPMorgan GBI-EM inclusion (June 2024): India was phased into the index from June 2024 to March 2025 at 1% per month, reaching the maximum 10% weight. Total FAR purchases between June 2024 and March 2025 reached ₹1.09 trillion — but much was front-loaded. Post-completion, FPIs became net sellers of FAR G-secs in FY26, underscoring that index inclusion alone does not guarantee sustained inflows without active fund participation (now enabled by the tax exemption).
- Bloomberg EM Local Currency Bond Index (January 2026): India’s bonds were added to Bloomberg’s index from January 2026. The June 2026 FAR expansion to 15/30/40-year G-secs deepens the investable universe for Bloomberg index trackers and long-duration sovereign bond mandates — expected to attract additional passive inflows as fund managers update their benchmark allocations.
7 — Prelims Pointers
MPC Mandate — CPI inflation targeting within 4% ±2% band; 6-member body (3 RBI + 3 Govt); Governor chairs; decisions by majority vote; exchange rate is NOT in MPC’s mandate — it falls under RBI’s broader mandate
FAR (Fully Accessible Route) — No FPI investment limits on specified G-secs; basis for JPMorgan GBI-EM (June 2024) and Bloomberg EM index (January 2026) inclusions; June 2026 expanded to 15/30/40-year G-secs
FCNR(B) Deposits — Foreign Currency Non-Resident Bank; held in foreign currency by NRIs; freely repatriable; RBI’s concessional hedging subsidy reduces banks’ cost of mobilising these deposits; key BOP stabiliser
Real Policy Rate — Nominal repo rate minus CPI inflation; at 5.25% repo and 5.1% CPI, India’s real rate is ~0.15% — near zero; low real rate justifies holding rather than cutting, but not yet hiking
CAD (Current Account Deficit) — Trade deficit + services + remittances + investment income; India’s CAD projected to double to ~2% of GDP in FY27 from sub-1%; financed by FDI + FPI + NRI deposits + RBI forex reserves
Income-tax Amendment Ordinance 2026 — Entry 13D: exempts FII capital gains and interest income on G-secs; Entry 13E: same for BIS; removes tax friction limiting active fund participation post-index inclusion; issued via ordinance route for urgency
Exam note: Never conflate the MPC’s mandate (inflation targeting — sets repo rate) with the RBI’s broader mandate (exchange rate management, capital account, banking regulation). The June 2026 policy is a textbook illustration: MPC held rates on inflation logic; RBI Governor separately announced capital account measures for the rupee. This institutional distinction is a standard GS 3 question pattern and has appeared in multiple CSE Mains papers.
8 — Practice Mains Question
“The June 2026 MPC decision illustrates both the strengths and limitations of inflation targeting as a monetary policy framework in an open economy facing simultaneous supply-side shocks.” Critically examine with reference to the West Asia conflict, the rupee’s vulnerability, and India’s capital account toolkit.
GS 3 — Economy | 15 marks | ~250 words | Monetary Policy + Exchange Rate + Capital Flows
- Intro: Frame the June 2026 dilemma — simultaneous upward inflation revision (5.1%) and downward growth revision (6.6%) create a classic stagflationary bind. Introduce the MPC’s inflation-targeting mandate and its institutional separation from exchange rate management.
- Body 1 — Why the hold was correct: Supply-side inflation (crude + monsoon) cannot be addressed by rate hikes without disproportionate growth cost; real policy rate near zero but inflation within the 6% band; premature tightening risk; FII outflows ($28.6 billion) addressed separately through capital account tools.
- Body 2 — Limitations exposed: Inflation targeting cannot address supply-side shocks; exchange rate pressure forces a parallel policy response outside the MPC’s mandate; capital flight driven by global factors (US rates, MSCI weights) is beyond domestic monetary policy reach; CAD doubling to 2% of GDP creates structural financing pressure regardless of repo rate.
- Conclusion: The institutional separation between the MPC (inflation targeting) and the RBI (currency/capital account) worked well in June 2026. October/December 2026 meetings are live for rate hike(s) if food/fuel price generalisation occurs. Structural solutions — higher-quality FDI, deeper G-sec market, FCNR(B) maturity management — are needed beyond cyclical capital account measures.
9 — Practice MCQ
Consider the following statements about the June 2026 MPC decision and associated RBI measures:
1. The MPC unanimously held the repo rate at 5.25% and revised the FY27 CPI inflation forecast upward to 5.1% while revising the GDP growth forecast downward to 6.6%.
2. The Fully Accessible Route (FAR) allows unlimited FPI investment in all categories of Government Securities without any sectoral sub-limits.
3. The Income-tax Amendment Ordinance 2026 exempts FIIs from capital gains tax and withholding tax on interest income from Government Securities.
4. India’s inclusion in the JPMorgan GBI-EM Bond Index was completed in January 2026, following which Bloomberg also included India’s bonds in its EM index.
Which of the statements are correct?
(a) 1 and 3 only
(b) 1, 2 and 3 only
(c) 2, 3 and 4 only
(d) 1, 3 and 4 only
1. The MPC unanimously held the repo rate at 5.25% and revised the FY27 CPI inflation forecast upward to 5.1% while revising the GDP growth forecast downward to 6.6%.
2. The Fully Accessible Route (FAR) allows unlimited FPI investment in all categories of Government Securities without any sectoral sub-limits.
3. The Income-tax Amendment Ordinance 2026 exempts FIIs from capital gains tax and withholding tax on interest income from Government Securities.
4. India’s inclusion in the JPMorgan GBI-EM Bond Index was completed in January 2026, following which Bloomberg also included India’s bonds in its EM index.
Which of the statements are correct?
Answer: (a) — 1 and 3 only
Statement 1 — Correct. June 5, 2026 MPC: unanimous hold at 5.25%; CPI raised 50 bps to 5.1%; GDP cut 30 bps to 6.6%. All three numbers are frequently tested together.
Statement 2 — Wrong. FAR allows unlimited FPI investment only in specified G-secs designated under the route — not all categories. The General Route still has investment sub-limits. FAR is expanded periodically; the June 2026 expansion added new 15/30/40-year maturities to the specified list.
Statement 3 — Correct. The Income-tax Amendment Ordinance 2026 (Entry 13D) specifically exempts FII capital gains on G-sec transfers and interest income — removing the tax friction that limited active fund participation beyond passive index-tracking inflows.
Statement 4 — Wrong in sequence. JPMorgan GBI-EM inclusion was phased from June 2024 to March 2025 (not January 2026). Bloomberg EM Local Currency Bond Index inclusion began January 2026. The two indices and their inclusion timelines are distinct — a classic chronology-confusion trap in Prelims.
Statement 1 — Correct. June 5, 2026 MPC: unanimous hold at 5.25%; CPI raised 50 bps to 5.1%; GDP cut 30 bps to 6.6%. All three numbers are frequently tested together.
Statement 2 — Wrong. FAR allows unlimited FPI investment only in specified G-secs designated under the route — not all categories. The General Route still has investment sub-limits. FAR is expanded periodically; the June 2026 expansion added new 15/30/40-year maturities to the specified list.
Statement 3 — Correct. The Income-tax Amendment Ordinance 2026 (Entry 13D) specifically exempts FII capital gains on G-sec transfers and interest income — removing the tax friction that limited active fund participation beyond passive index-tracking inflows.
Statement 4 — Wrong in sequence. JPMorgan GBI-EM inclusion was phased from June 2024 to March 2025 (not January 2026). Bloomberg EM Local Currency Bond Index inclusion began January 2026. The two indices and their inclusion timelines are distinct — a classic chronology-confusion trap in Prelims.
Editorial 02 of 02
Article 02
India Needs Innovative Strategies to Eliminate TB
Relevance: National TB Elimination Programme, PreVenTB Phase III trial, vaccine policy under uncertainty, Make-in-India in healthcare — directly relevant to GS 2 (Health, Governance) and GS 3 (Science & Technology) with strong Interview and Essay value on India’s public health decision-making frameworks.
GS 2 — Health & Governance
GS 3 — Science & Technology
Essay — Innovation & Public Health
1 — Issue in Brief
- More than a century after the BCG vaccine, TB remains the world’s deadliest infectious disease — killing 1.2 million people globally in 2024, more than COVID-19 at its peak — yet there is still no effective vaccine for adolescents and adults. India alone accounts for ~26% of global TB cases, carrying the world’s highest national burden.
- The PreVenTB trial (BMJ 2026) — the world’s first Phase III trial to evaluate vaccine efficacy against both pulmonary TB (PTB) and extrapulmonary TB (EPTB) in individuals aged 6 and above — provides India with an actionable, real-world signal. VPM1002 showed 50.4% efficacy against EPTB (statistically significant) across all age groups.
- The article’s central argument: India must act on available evidence rather than wait indefinitely for a “perfect” universal TB vaccine. The delay has a quantifiable mortality cost — and India has a well-established institutional precedent for deploying imperfect but effective health tools under urgency (TrueNat, Covaxin, indigenous rotavirus vaccine).
- The policy ask is not a blanket national rollout — it is targeted, risk-stratified deployment: among household contacts of TB patients (highest-risk defined population), school-age children (6–14 years, where efficacy exceeded 65%), and in convergence with nutrition programmes where low BMI reduces vaccine response.
2 — Static Background
- Mycobacterium tuberculosis infects ~25% of the world’s population in latent form. Active TB may manifest as Pulmonary TB (PTB) — the infectious form driving person-to-person transmission — or Extrapulmonary TB (EPTB), which affects lymph nodes, spine (Pott’s disease), brain (TB meningitis), kidney, and pleura. EPTB is harder to diagnose, frequently missed in routine surveillance, and disproportionately affects women and children.
- The BCG (Bacille Calmette-Guérin) vaccine — the only licensed TB vaccine — has been in use since 1921 and protects infants and young children against severe forms (TB meningitis, miliary TB) but provides little to no protection against pulmonary TB in adolescents and adults, the primary transmission-sustaining age group. India administers BCG at birth under the Universal Immunisation Programme (UIP).
- The National TB Elimination Programme (NTEP) (renamed from RNTCP in 2020) aims to eliminate TB in India by 2025 — a target already acknowledged as missed and revised to 2030 (aligned with SDG 3.3). The programme operates through the Nikshay portal (digital case notification and treatment tracking), Directly Observed Treatment Short-course (DOTS), and a robust household contact investigation framework that already identifies the high-risk population where VPM1002 would be deployed.
- VPM1002 is a recombinant BCG vaccine developed at the Max Planck Institute for Infection Biology, licensed to Vakzine Projekt Management, and sublicensed to Serum Institute of India (SIIPL) — the world’s largest vaccine manufacturer by volume. It contains a modified BCG strain with enhanced immune activation. Single-dose, cold-chain compatible, and manufactureable at massive scale by SIIPL gives it decisive operational advantages for a country of India’s geographic and demographic complexity.
- Immuvac (Mycobacterium Indicus Pranii / MIP) is an indigenous Indian vaccine candidate developed by Cadila Healthcare. It is a heat-killed mycobacterium preparation with immunomodulatory properties, previously tested in leprosy and as a TB adjunct therapy. The PreVenTB trial is its first large-scale efficacy evaluation as a standalone preventive vaccine in a high-risk community setting.
- CDSCO (Central Drugs Standard Control Organisation) is India’s national drug and vaccine regulatory authority under the Ministry of Health. It approves vaccines through standard licensure, conditional approval, or accelerated pathways (as used for Covaxin in “clinical trial mode” during COVID-19). The PreVenTB trial’s Phase III data published in the BMJ now creates the evidentiary basis for a CDSCO application — the regulatory pathway the editorial implicitly calls for.
3 — Key Dimensions
- PreVenTB trial design — what makes it unique: 12,717 household contacts aged 6+ across 18 sites in 6 Indian states; July 2019 – December 2020 enrolment; 38 months follow-up; 96.7% completion rate (exceptionally high for any Indian trial). Three arms: VPM1002, Immuvac, placebo. First Phase III trial globally to include EPTB as a primary efficacy endpoint — all prior TB vaccine trials, including all currently ongoing global trials, evaluate only pulmonary TB outcomes.
- Efficacy findings in full (BMJ 2026): VPM1002 — 50.4% against EPTB (all ages, statistically significant); 64.9% against EPTB in TST-positive participants; ~65% against all TB in children 6–14 years. Immuvac — 33.2% against EPTB (all ages); 66.3% in TST-positive participants; ~66% against EPTB in children 6–10 years. Neither vaccine showed significant efficacy against pulmonary TB or latent TB across all age groups — a critical limitation the editorial acknowledges.
- Why EPTB efficacy matters clinically and programmatically: EPTB is the “hidden burden” of the TB epidemic — frequently not counted in headline TB incidence statistics, yet responsible for significant hospitalisation, disability, and mortality. A >50% reduction in EPTB cases means fewer spinal TB admissions, less TB meningitis, reduced diagnostic delays, lower healthcare costs, and meaningfully less suffering concentrated among women and children who bear disproportionate EPTB burden.
- Nutrition as an inseparable co-factor: Reduced vaccine efficacy in individuals with low BMI is the trial’s most policy-relevant secondary finding. India has ~189 million undernourished people (FAO 2024) — a significant overlap with TB high-burden populations. This finding mandates convergence with Poshan Abhiyaan, PM Garib Kalyan Anna Yojana, Mid-Day Meal Scheme, and Nikshay Poshan Yojana (nutritional support for TB patients) for any vaccine rollout to deliver its full efficacy in the field.
- India’s precedents for acting on imperfect evidence: TrueNat — adopted under NTEP before WHO pre-qualification; Covaxin — approved in “clinical trial mode” during COVID-19 before complete Phase III data; Rotavirus vaccine — introduced with modest efficacy and wide confidence intervals (Bhandari et al., The Lancet, 2014), now part of the national immunisation programme after demonstrating real-world impact on severe child diarrhoeal mortality. Each precedent reflects India’s willingness to deploy domestically developed tools under urgency — a framework directly applicable to VPM1002.
- Operational case for VPM1002 over alternatives: Of 16 TB vaccine candidates globally in the pipeline, most are multi-dose, adjuvanted formulations requiring complex cold chain and trained administration. VPM1002 is a single-dose BCG-platform vaccine manufactured by SIIPL at scale. For a country deploying through 30,000+ NTEP treatment centres and sub-centres, logistical simplicity is a decisive programmatic advantage that no imported candidate can match in the near term.
4 — Critical Analysis
- Favour — EPTB efficacy is a genuine global breakthrough: No other TB vaccine trial globally has used EPTB as a primary efficacy endpoint — not M72/AS01E, not H4:IC31, not any currently active Phase III trial. The 50.4% VPM1002 EPTB efficacy reframes both the clinical utility question and the trial design standard for global TB vaccine research, with India’s ICMR-led trial setting the methodological precedent.
- Favour — Targeted deployment is both rational and feasible: India’s NTEP already has household contact investigation infrastructure. Deploying VPM1002 within this existing mechanism targets the highest-risk, most readily identified population with minimal additional system cost. The 6–14 year school-age finding (>65% efficacy) further opens a complementary school-based immunisation channel through Mission Indradhanush.
- Favour — Delay has a concrete mortality cost: India notifies 2.5–2.8 million TB cases annually. At current treatment success rates, hundreds of thousands of cases result in death or permanent disability every year. Each year of policy inaction on a vaccine with demonstrated efficacy against EPTB — which accounts for ~20% of all TB cases in India — represents a preventable burden that waiting for a “perfect” vaccine cannot justify.
- Concern — Pulmonary TB efficacy gap is not trivial: PTB drives ~80% of TB transmission in India. A vaccine with no demonstrated PTB efficacy does not reduce the primary reproduction number of the epidemic — meaning EPTB reduction, while clinically valuable, does not alone bend the epidemiological curve toward elimination. The editorial’s framing of VPM1002 as part of a layered strategy is correct; presenting it as a core elimination tool would be epidemiologically overstated.
- Concern — Regulatory pathway needs explicit articulation: The editorial calls for deployment without specifying the CDSCO pathway — conditional approval, restricted use licence, or expanded clinical trial mode. Each pathway has different post-marketing obligation requirements, indemnity frameworks, and programme integration timelines. Without a clear regulatory roadmap, programmatic integration cannot proceed regardless of the trial’s scientific strength.
- Concern — Nutrition-vaccine interaction creates equity risk: If low BMI reduces efficacy and VPM1002 is deployed without mandatory nutritional screening and supplementation, the vaccine will systematically underperform in the most marginalised communities — creating a two-tier protection outcome where those most at risk of TB (poorest, most malnourished) benefit least. This is not a minor implementation detail; it is a social justice dimension requiring explicit policy design.
5 — Way Forward
- Conditional/restricted use approval by CDSCO for VPM1002 among household contacts of diagnosed TB patients and school-age children (6–14) in high-burden districts — with active pharmacovigilance and post-marketing efficacy monitoring built in from day one, following the Covaxin “clinical trial mode” precedent that successfully balanced urgency with continued data accumulation.
- Integration with NTEP’s existing contact tracing infrastructure — India’s household contact investigation framework under NTEP is already functional at scale. VPM1002 deployment within this mechanism targets the right population, uses existing health worker networks, and avoids duplicating programme infrastructure — the most cost-effective implementation pathway available.
- Mandatory convergence with nutrition schemes — BMI screening and nutritional supplementation (via Nikshay Poshan Yojana, PMGKAY) as a co-condition for VPM1002 deployment in districts with high malnutrition prevalence. This ensures the vaccine is administered in conditions where its efficacy is not systematically blunted by host nutritional deficiency — addressing the trial’s secondary finding as a first-order implementation requirement.
- Fast-track WHO pre-qualification of VPM1002 — SIIPL’s manufacturing scale and cost structure means India can supply VPM1002 to other high-burden LMICs at a fraction of the cost of imported alternatives. Indian CDSCO approval and subsequent WHO pre-qualification review would create a global supply opportunity, extend India’s vaccine diplomacy beyond COVID-19, and recover the “pharmacy of the world” positioning in the TB space.
6 — Data & Key Facts
10.7 MnGlobal TB cases in 2024 (WHO Global TB Report)
1.2 MnGlobal TB deaths in 2024 — more than COVID-19 at its peak
~26%India’s share of global TB burden — world’s highest national caseload
12,717PreVenTB trial participants; 18 sites; 6 states; 38-month follow-up; 96.7% retention
50.4%VPM1002 efficacy against EPTB (all ages) — statistically significant (BMJ 2026)
>65%VPM1002 efficacy against all TB in children 6–14 years; Immuvac EPTB efficacy 6–10 yrs
- NTEP elimination target: <10 cases per 100,000 population. India’s current incidence is ~193 per 100,000 — nearly 20× the elimination threshold. Target was 2025 (missed); revised to 2030 under SDG 3.3. NTEP tracks 2.5–2.8 million new notifications annually via the Nikshay portal.
- PreVenTB trial citation: Singh M et al., “Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial),” BMJ 2026; 393: e085716. doi: 10.1136/bmj-2025-085716. Funded by India TB Research Consortium (ITRC) and ICMR. Only Phase III trial globally to include EPTB as a primary efficacy endpoint.
- 16 TB vaccine candidates currently in global pipeline (WHO, 2024) — VPM1002 and Immuvac are among the most advanced for post-exposure/preventive use. Most others are multi-dose adjuvanted formulations with no EPTB efficacy data. VPM1002’s single-dose BCG-platform design and SIIPL manufacture give it a decisive operational advantage for large-scale deployment in LMICs.
7 — Prelims Pointers
EPTB (Extrapulmonary TB) — TB affecting organs outside the lungs (lymph nodes, spine, brain, kidney, pleura); harder to diagnose; ~20% of India’s TB burden; PreVenTB is the first Phase III trial globally to include it as efficacy endpoint
VPM1002 — Recombinant BCG; Max Planck Institute origin; sublicensed to SIIPL (Serum Institute); single dose; 50.4% EPTB efficacy (all ages); >65% all-TB efficacy in children 6–14 yrs (BMJ 2026)
Immuvac (MIP) — Mycobacterium Indicus Pranii; developed by Cadila Healthcare; two-dose; 33.2% EPTB efficacy (all ages); 66.3% in TST-positive participants; first standalone preventive vaccine trial for Immuvac
NTEP — National TB Elimination Programme (renamed from RNTCP, 2020); target 2030 elimination; Nikshay portal for case tracking; DOTS; household contact investigation framework; PM-TB Mukt Bharat Abhiyan
TrueNat — Make-in-India molecular TB diagnostic; adopted under NTEP before WHO pre-qualification; manufactured by Molbio Diagnostics (Goa); precedent for early domestic adoption of Indian health technology
Nikshay Poshan Yojana — ₹500/month nutritional support for TB patients under NTEP; directly relevant as co-intervention for vaccine deployment given PreVenTB’s finding of reduced efficacy in low-BMI individuals
Exam note: The distinction between PTB (pulmonary — infectious, drives transmission) and EPTB (extrapulmonary — non-infectious, higher morbidity) is frequently tested. Remember: PreVenTB’s key finding is VPM1002’s EPTB efficacy, not PTB efficacy (where neither vaccine showed significant effect). Do not confuse VPM1002 (recombinant BCG, SIIPL) with Immuvac/MIP (killed mycobacterium, Cadila) — both were tested in PreVenTB but are different platforms.
8 — Practice Mains Question
“India’s TB elimination strategy requires a layered, pragmatic approach that deploys available tools rather than waiting for a universal solution.” Critically examine with reference to the PreVenTB trial findings, India’s precedents in vaccine deployment under uncertainty, and the nutritional co-determinants of vaccine efficacy.
GS 2 — Health & Governance | 15 marks | ~250 words | TB Policy + Vaccine Governance + Public Health
- Intro: Frame India’s TB burden (~26% global caseload, 193 per 100,000 incidence, 2030 elimination target) and the BCG efficacy gap in adolescents/adults. Introduce PreVenTB as the first Phase III trial to evaluate EPTB efficacy — a methodological breakthrough with policy implications.
- Body 1 — The case for deployment: VPM1002’s 50.4% EPTB efficacy and >65% all-TB efficacy in children 6–14; EPTB as the hidden burden; SIIPL’s manufacturing capacity; India’s NTEP household contact tracing infrastructure as ready deployment vehicle; TrueNat/Covaxin/rotavirus vaccine as policy precedents for acting on imperfect evidence.
- Body 2 — Concerns requiring policy design: No PTB efficacy (does not bend the transmission curve); unclear CDSCO regulatory pathway; nutrition-vaccine interaction creating equity risk for low-BMI populations who need protection most; false reassurance risk if positioned as a broader elimination tool.
- Conclusion: Conditional CDSCO approval targeting household contacts and school-age children via NTEP; mandatory BMI screening + Nikshay Poshan Yojana convergence; WHO pre-qualification for global LMIC supply; VPM1002 as one layer of a multi-tool TB strategy — not a standalone solution but a meaningful, deployable component that India should not defer.
9 — Practice MCQ
Consider the following statements about the PreVenTB trial and TB vaccine policy in India:
1. The PreVenTB trial is the first Phase III clinical trial globally to evaluate vaccine efficacy against both pulmonary TB and extrapulmonary TB in individuals aged 6 years and above.
2. VPM1002 showed statistically significant efficacy of 50.4% against extrapulmonary TB across all age groups, while Immuvac showed 33.2% efficacy against extrapulmonary TB.
3. Both VPM1002 and Immuvac demonstrated significant efficacy against pulmonary TB and latent TB infection across all age groups in the PreVenTB trial.
4. TrueNat, India’s Make-in-India molecular TB diagnostic, was adopted under NTEP before receiving WHO pre-qualification — a precedent cited for early deployment of domestically developed health tools.
Which of the statements are correct?
(a) 1 and 2 only
(b) 1, 2 and 4 only
(c) 2 and 4 only
(d) 1, 2, 3 and 4
1. The PreVenTB trial is the first Phase III clinical trial globally to evaluate vaccine efficacy against both pulmonary TB and extrapulmonary TB in individuals aged 6 years and above.
2. VPM1002 showed statistically significant efficacy of 50.4% against extrapulmonary TB across all age groups, while Immuvac showed 33.2% efficacy against extrapulmonary TB.
3. Both VPM1002 and Immuvac demonstrated significant efficacy against pulmonary TB and latent TB infection across all age groups in the PreVenTB trial.
4. TrueNat, India’s Make-in-India molecular TB diagnostic, was adopted under NTEP before receiving WHO pre-qualification — a precedent cited for early deployment of domestically developed health tools.
Which of the statements are correct?
Answer: (b) — 1, 2 and 4 only
Statement 1 — Correct. PreVenTB (BMJ 2026) is the first Phase III trial globally to include EPTB as a primary efficacy endpoint. No other currently active global TB vaccine trial has EPTB as an efficacy outcome — a key distinguishing fact for Prelims.
Statement 2 — Correct. VPM1002: 50.4% EPTB efficacy (all ages, statistically significant). Immuvac: 33.2% EPTB efficacy (all ages). Both figures are directly from the BMJ 2026 publication and are the most cited data points from the trial.
Statement 3 — Wrong. This is the critical exam trap. Neither VPM1002 nor Immuvac showed significant efficacy against pulmonary TB or latent TB infection across all age groups — these are the trial’s explicit limitations. The efficacy signals are for EPTB and for specific age subgroups (children 6–14), not for PTB broadly.
Statement 4 — Correct. TrueNat was adopted under NTEP before WHO pre-qualification — a precedent the article explicitly cites alongside Covaxin and the rotavirus vaccine as evidence of India’s institutional willingness to deploy domestically developed health tools ahead of full global validation.
Statement 1 — Correct. PreVenTB (BMJ 2026) is the first Phase III trial globally to include EPTB as a primary efficacy endpoint. No other currently active global TB vaccine trial has EPTB as an efficacy outcome — a key distinguishing fact for Prelims.
Statement 2 — Correct. VPM1002: 50.4% EPTB efficacy (all ages, statistically significant). Immuvac: 33.2% EPTB efficacy (all ages). Both figures are directly from the BMJ 2026 publication and are the most cited data points from the trial.
Statement 3 — Wrong. This is the critical exam trap. Neither VPM1002 nor Immuvac showed significant efficacy against pulmonary TB or latent TB infection across all age groups — these are the trial’s explicit limitations. The efficacy signals are for EPTB and for specific age subgroups (children 6–14), not for PTB broadly.
Statement 4 — Correct. TrueNat was adopted under NTEP before WHO pre-qualification — a precedent the article explicitly cites alongside Covaxin and the rotavirus vaccine as evidence of India’s institutional willingness to deploy domestically developed health tools ahead of full global validation.
